Infosys has extended Tuesday's gains this morning after inking a deal with GlaxoSmithKline to optimize digital channels across its global consumer healthcare and pharma business lines.
The digital marketing platform will allow GSK to build digital assets and listen to consumers across an array of digital channels. The platform will allow teams to collaborate through superior work flow capabilities and foster re-use of digital assets.
The stock opened at Rs 2,885 and surged to a high of Rs 2,915. The stock is now up 1.3% at Rs 1,896. Shares of Infosys had surged 1.5% in trades yesterday. The counter has seen comparatively heft trades of around 38,000 shares so far on the BSE, as against a two-week trading average of 58,000 shares.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app